Morgans's healthcare analyst Iain Wilkie describes 2024 as "pretty patchy" for the ASX healthcare sector, which has ...

IMP761, an experimental immunotherapy Immutep is developing for multiple sclerosis (MS) and other autoimmune conditions, has shown a promising safety profile in an ongoing Phase 1 clinical trial ...

Verition Fund Management LLC’s holdings in Immutep were worth $57,000 at the end of the most recent quarter. Other hedge funds have also added to or reduced their stakes in the company.

Dr. Frédéric Triebel, CSO of Immutep, said: "We are very encouraged by the safety data generated to date for IMP761, the world's first LAG-3 agonist antibody, in this Phase I setting.

Clinical-stage company Immutep (ASX:IMM) has announced new findings published in Science Immunology that resolve how human lymphocyte activation gene 3 (LAG-3) binds to its main ligand MHC Class II ...

Immutep reports no adverse events in Phase I trial of IMP761, a LAG-3 agonist for autoimmune diseases, with more data expected in 2025. Immutep Limited has released promising initial safety data ...

Favourable safety profile for world’s first LAG-3 agonist, IMP761, with no treatment related adverse events to dateAdditional ...

Dr. Frédéric Triebel, CSO of Immutep, said:“We are very encouraged by the safety data generated to date for IMP761, the world's first LAG-3 agonist antibody, in this Phase I setting.

Findings published in Science Immunology resolve how human LAG-3 binds to its main ligand providing a better foundation for development of blocking LAG-3 therapeutics, including Immutep’s anti-LAG-3 ...

Dr. Frédéric Triebel, CSO of Immutep, said: “We are very encouraged by the safety data generated to date for IMP761, the world’s first LAG-3 agonist antibody, in this Phase I setting.

The year is ending with a bang rather than a whimper in biotech land, with a steady flow of clinical trials news likely to ...